

Scientific Poster Presentations, III

Wednesday, October 19

Convention Center: Exhibit Hall A

8:00 a.m.–10:00 a.m.

ENCORE PRESENTATIONS

Abstracts marked with an “E” are Encore Presentations. Encore Presentations undergo the same peer-review process as all other presentations, but they may have been presented elsewhere or published in abstract form before the 2011 Annual Meeting. For presentations, the abstract title, authors, and original citation (if provided) are published.

FINALISTS IN ABSTRACT AWARDS COMPETITION

Abstracts marked with an “F” are finalists for the Best Resident and Fellow Poster and Best Paper Awards. These papers were selected by a special panel of reviewers.

ORIGINAL RESEARCH

These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoeconomics, and pharmacoepidemiology.

Ambulatory Care

20. Impact of a Medication Therapy Management Program on Hemoglobin A1c Values in a Health Resources and Services Administration Patient Safety and Clinical Pharmacy Services Collaborative.

Heather B. Congdon, Pharm.D.,¹ Iliana Cheng, Pharm.D.,¹ Hoai An Truong, Pharm.D.,² Faramarz Zarfeshan, R.Ph.,³ Thomas C. Dowling, Pharm.D., Ph.D.,⁴ (1)University of Maryland School of Pharmacy, Rockville, MD; (2)University of Maryland School of Pharmacy, Baltimore, MD; (3)ALFA Specialty Pharmacy, Silver Spring, MD; (4)University of Maryland, School of Pharmacy, Baltimore, MD

Cardiovascular

40E. Influence of Global Region on Outcomes in Large Heart Failure β -Blocker Trials.

Mona Fiuzat, Pharm.D.,¹ Christopher O'Connor, M.D.,¹ Karl Swedberg, M.D.,² Michael Caron, Pharm.D.,³ Bruce R. Koch II, Pharm.D.,³ Peter E. Carson, M.D.,⁴ Wendy A. Gattis-Stough, Pharm.D.,⁵ Gordon Davis, MSPH,⁶ Michael R. Bristow, M.D., Ph.D.,⁷ (1) Duke University Medical Center, Division of Clinical Pharmacology, Durham, NC; (2) Sahlgrenska University Hospital, Goteborg, Sweden; (3)Gilead, Foster City, CA; (4) Department of Veterans Affairs, Washington, DC; (5)Expert Medical Communications, Durham, NC; (6)ARCA biopharma, Inc, Broomfield, CO; (7)University of Colorado Health Sciences Center, Denver, CO

Community Pharmacy Practice

43. Pharmacists' and Pharmacy Students' Knowledge and Attitudes Regarding Patients with Disabilities in Qatar.

Sara Al-Dahir, Pharm.D., BCPS,¹ Barbara Hong, Ph.D.,² Rihab Kaissi, B.S.,³ Amaal Gulied, B.S.³; (1)Xavier University of Louisiana, New Orleans, LA; (2)Pennsylvania State University, Altoona, PA; (3)Qatar University, Doha, Qatar

Drug Information

60. The Prevalence and Quality of Noninferiority Studies in Major Medical Journals.

McKenzie C. Ferguson, Pharm.D., BCPS, Erin M. Timpe, Pharm.D., BCPS, Jeff Harp, Pharm.D.; Southern Illinois University–Edwardsville, Edwardsville, IL

Emergency Medicine

90. The Combination of Prothrombin Complex Concentrate, Factor VIIa, and Phytonadione to Reverse Elevated International Normalized Ratio.

Bryce J. Bitton, Pharm.D., Kevin P. Myers, Pharm.D., C. Dustin Waters, Pharm.D.; McKay-Dee Hospital, Ogden, UT

91. Retrospective Review of NPO Status in Children Receiving Ketamine for Procedural Sedation in the Emergency Department.

Megan E. Foster, Pharm.D.; Le Bonheur Children's Medical Center, Department of Pharmacy, Memphis, TN

92. Incidence and Characteristics of Antithrombotic Errors in the Emergency Department.

Aaron J. Prince, Pharm.D.,¹ Stephen Rolfe, Pharm.D., BCPS,² Jeffrey Dandurand, Pharm.D., BCPS,³ Kimberly A. Pesaturo, Pharm.D., BCPS⁴; (1)UMass Memorial Medical Center, Worcester, MA; (2)University of New England, College of Pharmacy, Portland, ME; (3) Clinical Pharmacy Associates, Laurel, MD; (4)Massachusetts College of Pharmacy and Health Sciences – Worcester/Manchester, Worcester, MA

93. Intranasal Fentanyl and Midazolam Use in a Pediatric Emergency Department.

Megan E. Foster, Pharm.D.; Le Bonheur Children's Medical Center, Department of Pharmacy, Memphis, TN

Gastroenterology

100. Are Proton Pump Inhibitors Associated with the Development of Community-Acquired Pneumonia: A Meta-analysis.

Christopher A. Giuliano, Pharm.D.,¹ Sheila M. Wilhelm, Pharm.D., BCPS,² Pramodini B. Kale-Pradhan, Pharm.D.¹; (1)Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences and St. John Hospital and Medical Center, Detroit, MI; (2) Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences and Harper University Hospital, Detroit, MI

101E. A Multicenter, Double-Blind, Parallel-Group Study to Evaluate Short-term Safety and Efficacy and Long-term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formulation in 1- to 11-Year-Old Pediatric Subjects with Endoscopically Proven GERD.

Gerhard J. Leitz, M.D., Ph.D.,¹ Ibrahim Haddad Sr, M.D.,² Steven Silber, M.D.,³ Andrew Mulberg, M.D.¹; (1)Johnson & Johnson Pharmaceutical Research & Development, LLC, Titusville, NJ; (2)Pediatric & Adolescent Gastroenterology & Nutrition, Youngstown, OH, (3)Johnson and Johnson PRD, Titusville, NJ

Health Services Research

109. Combining a Clinical Pharmacy Economic Intervention Tool with an Intervention Documentation System.

Adam B. Pesaturo, Pharm.D., Erin Taylor, Pharm.D., Caryn Colburn, B.S., Audrey Bernard, Pharm.D., Mark Heelon, Pharm.D.; Baystate Medical Center, Springfield, MA

HIV/AIDS

120. Comparison of Clinical Outcomes Between Ritonavir-Boosted Atazanavir and Unboosted Atazanavir in HIV Patients on a Regimen Containing Tenofovir.

James D. Scott, Pharm.D., M.Ed., FCCP,¹ Kevin T. Marx, Pharm.D.,² Robert K. Bolan, M.D.²; (1)Western University of Health Sciences, Pomona, CA; (2)Jeffrey Goodman Clinic, Los Angeles, CA

121E. Hepatic Safety Profile of Fosamprenavir-Containing Regimens in HIV-1-Infected Patients with or without Hepatitis C or B Co-infection.

Belinda F. Ha, Ph.D.,¹ Brian C. Wine, M.S.,¹ Michael E. Wisniewski, Ph.D.,¹ Felipe Rodríguez-Alcántara, M.D.,² *Mark S. Shaefer, Pharm.D.*³; (1)GlaxoSmithKline, Research Triangle Park, NC; (2)ViiV Health Care, Madrid, Spain; (3)ViiV Health Care, Research Triangle Park, NC

122E. Efficacy and Safety of Abacavir/Lamivudine Plus Raltegravir at Week 96 in Antiretroviral-Naive HIV-1-Infected Patients in the SHIELD Study.

Benjamin Young, M.D., Ph.D.,¹ Thanos J. Vanig, M.D.,² Edwin DeJesus, M.D.,³ Trevor N. Hawkins, M.D.,⁴ Marty St. Clair, B.S.,⁵ Britt S. Stancil, B.S.,⁵ *Belinda F. Ha, Ph.D.*⁵; (1) Division of General Internal Medicine, University of Colorado, Denver, CO; (2)Spectrum Medical Group, Phoenix, AZ; (3)Orlando Immunology Center, Orlando, FL; (4)Southwest Care Clinic, Santa Fe, NM; (5)GlaxoSmithKline, Research Triangle Park, NC

123E. Efficacy/Tolerability of Unboosted Atazanavir versus Atazanavir/Ritonavir, Each in Combination with Abacavir/Lamivudine, After Initial Suppression with Abacavir/Lamivudine + Atazanavir/Ritonavir in HIV-1-Infected Patients: 144-Week Results of ARIES.

Kathleen E. Squires, M.D.,¹ Benjamin Young, M.D., Ph.D.,² Edwin DeJesus, M.D.,³ Nicholaos C. Bellos, M.D.,⁴ Daniel Murphy, M.D.,⁵ Henry Zhao, Ph.D.,⁶ Lisa L. Ross, M.S.,⁶ *Mark S. Shaefer, Pharm.D.*⁷; (1)Thomas Jefferson University, Philadelphia, PA; (2) Division of General Internal Medicine, University of Colorado, Denver, CO; (3)Orlando Immunology Center, Orlando, FL; (4)Southwest Infectious Disease Associates, Dallas, TX; (5)Clinique Medicale L'Actuel, Montreal, Quebec, Canada; (6)GlaxoSmithKline, Research Triangle Park, NC; (7)ViiV Health Care, Research Triangle Park, NC

124E. Switch to Fosamprenavir with Addition of Lovaza for Management of Hypertriglyceridemia in HIV-Infected Patients on Boosted Protease Inhibitor Regimens: A Pilot Study (BULLET).

Franco Felizarta, M.D.,¹ Anthony Scarsella, M.D.,² Homayoon Khanlou, M.D.,³ John D. Stansell, M.D.,⁴ Winston Young, B.S.,⁵ Lisa L. Ross, M.S.,⁶ Henry Zhao, Ph.D.,⁶ Keith A. Pappa, Pharm.D.,⁶ *Belinda F. Ha, Ph.D.*⁶; (1)Franco Felizarta, M.D., Bakersfield, CA; (2) Pacific Oaks Medical Group, Beverly Hills, CA; (3)AIDS Health Care Foundation, Los Angeles, CA; (4)Private Practice, Palm Springs, CA; (5)Statworks, Inc, Research Triangle Park, NC; (6)GlaxoSmithKline, Research Triangle Park, NC

125. Effects of Darunavir, Ritonavir, and Darunavir/Ritonavir on T-cell Activation and Apoptosis Using HIV-Negative CD4+ Lymphocytes.

James D. Scott, Pharm.D., M.Ed., B.S., Stephen A. O'Barr, Ph.D.; Western University of Health Sciences, Pomona, CA

126E. Changes in Inflammatory Biomarker Levels and Correlation with Framingham (FRAM) Risk Scores in Antiretroviral-Naive HIV-Infected Patients Through 144 Weeks of Abacavir/Lamivudine-Containing Therapy in ARIES (EPZ108859).

Benjamin Young, M.D., Ph.D.,¹ Kathleen E. Squires, M.D.,² Lisa L. Ross, M.S.,³ Lizette Santiago, M.D.,⁴ Louis M. Sloan, M.D.,⁵ Henry Zhao, Ph.D.,³ Brian C. Wine, M.S.,³ Margaret W. Schultz, M.S.,³ David A. Margolis, M.D.,³ *Mark S. Shafer, Pharm.D.*⁶; (1) Division of General Internal Medicine, University of Colorado, Denver, CO; (2)Thomas Jefferson University, Philadelphia, PA; (3)GlaxoSmithKline, Research Triangle Park, NC; (4)HOPE Clinical, San Juan, PR; (5)North Texas IDC, Dallas, TX; (6)ViiV Health Care, Research Triangle Park, NC

Infectious Diseases

127. Candidemia Pharmacotherapy over Eight Years at a Tertiary Medical Center.

Thy Le, Pharm.D.,¹ *Jason C. Gallagher, Pharm.D.*²; (1)Temple University Hospital, Philadelphia, PA; (2)Temple University School of Pharmacy, Philadelphia, PA

128E. Predictors of Mortality Among Elderly Patients with Gram-negative Bloodstream Infection.

Travis Ledford, Pharm.D./MSCR Candidate,¹ Chad Cannon, Pharm.D./MSCR Candidate,¹ John B. Hughes, Pharm.D./MSCR Candidate,¹ Christopher D. Pfeiffer, M.D., MHS,² Luke F. Chen, MBBS, MPH,² Melissa Johnson, Pharm.D., MHS,³ Deverick Anderson, M.D., MPH²; (1)Campbell University College of Pharmacy & Health Sciences, Morrisville, NC; (2)Duke University Medical Center, Durham, NC; (3)Duke University Medical Center and Campbell University College of Pharmacy & Health Sciences, Durham, NC

129. A Comparison of Patients with *Klebsiella* Bacteremia with Imipenem Resistance to Those with Third-Generation Cephalosporin Resistance.

Jason Gallagher, Pharm.D.,¹ Prachi D. Bhatt, Pharm.D.,² Elizabeth Marino, Pharm.D.³; (1) Temple University School of Pharmacy, Philadelphia, PA; (2)Temple University Hospital, Philadelphia, PA; (3)Pennsylvania Hospital, Philadelphia, PA

130. Mitochondrial Toxicity with Caspofungin.

Kayla R. Stover, Pharm.D., BCPS,¹ Jonathan P. Hosler, Ph.D.,² John D. Cleary, Pharm.D.²; (1)The University of Mississippi School of Pharmacy, Jackson, MS; (2)University of Mississippi Medical Center, Jackson, MS

131. A Retrospective Comparison of Daptomycin Thrice-Weekly versus Q48H Dosing in Hemodialysis Patients with Vancomycin-Resistant *Enterococcus* or Methicillin-Resistant *Staphylococcus aureus* Bacteremia.

Katie L. Axford, Pharm.D., Dane L. Shiltz, Pharm.D., BCPS; Indiana University Health and Butler University, Indianapolis, IN

132. Assessment of Fluoroquinolone-Resistant Urinary Pathogens in Patients Admitted to an Acute Care Hospital from a Nursing Home.

Brian R. Lohr, Pharm.D.; University of Pittsburgh Medical Center, Pittsburgh, PA

133. Evaluation of Antibiotic Prescribing Patterns in Patients Receiving Sustained Low-Efficiency Dialysis.

Laura E. Harris, Pharm.D.,¹ Anne Reaves, Pharm.D.,¹ Amy Krauss, Pharm.D.,¹ Justin Griner, B.S.,² Joanna Q. Hudson, Pharm.D.²; (1)Methodist University Hospital, Memphis, TN; (2)The University of Tennessee College of Pharmacy, Memphis, TN

134. Identifying an Optimal Dose of Vancomycin in Morbidly Obese Patients.

Gary N. Elsasser, Pharm.D.,¹ Phillip S. Lorhan, Pharm.D.,² Christopher J. Destache, Pharm.D., FCCP¹; (1)Creighton University School of Pharmacy and Health Professions, Omaha, NE; (2)Creighton University Medical Center, Omaha, NE

135. *Pseudomonas aeruginosa* (PSA) Combination Antibiogram: Incorporating Pharmacodynamic Breakpoints (PDB) to Identify Most Appropriate Empiric Regimens.

Kathy Zhang, Pharm.D. Candidate, Gregory A. Eschenauer, Pharm.D., Brian A. Potoski, Pharm.D.; University of Pittsburgh Medical Center, Pittsburgh, PA

136. The Impact of a Gentamicin-Citrate Catheter Lock Intervention on Outpatient Hemodialysis Catheter-Associated Bloodstream Infections.

Christine Hamby, Pharm.D.,¹ Kristen Buczynski, Pharm.D. Candidate,¹ Michelle Vignari, R.N., CIC, AAS,¹ Miyako Newell, BSN,¹ Donna Farnsworth, R.N., MHA, CIC,² Stephen Silver, M.D.,¹ Edward Walsh, M.D.,¹ Alexandra Yamschikov, M.D.¹; (1)Rochester General Hospital, Rochester, NY; (2)Unity Health System, Rochester, NY

137E. Impact of NXL104 on Ceftaroline MICs for Bacteria Producing Extended-Spectrum, AmpC, or KPC β -Lactamases.

Robert E. Badal, B.S.,¹ Samuel Bouchillon, M.D.,¹ Meredith Hackel, Ph.D.,¹ Daryl Hoban, Ph.D.,¹ Christine Lascols, M.S.,¹ Stephen Hawser, Ph.D.,² Gregory Williams, Ph.D.³; (1) International Health Management Associates, Inc, Schaumburg, IL; (2)IHMA Europe Sàrl, Epalinges, Switzerland; (3)Cerexa, Inc (a wholly owned subsidiary of Forest Laboratories, Inc, New York, NY), Oakland, CA

138. New Dosing Recommendations for Vancomycin in Premature Infants.

Eric B. Hoie, Pharm.D., Justin Tolman, Pharm.D., Ph.D.; Creighton University School of Pharmacy and Health Professions, Omaha, NE

139E. Spectrum of Activity of Ceftaroline/NXL104 and β -Lactam Comparator Agents Tested Against Methicillin-Resistant *Staphylococcus aureus* Carrying Different SCCmec Types and Gram-negative Bacilli with Well-Characterized Resistance Mechanisms.

David J. Farrell, Ph.D.,¹ Rodrigo E. Mendes, Ph.D.,¹ *Gregory Williams, Ph.D.*,² Ian Critchley, Ph.D.,² Ronald N. Jones, M.D.,¹ Helio S. Sader, M.D., Ph.D.¹; (1)JMI Laboratories, North Liberty, IA; (2)Cerexa, Inc (a wholly owned subsidiary of Forest Laboratories, Inc, New York, NY), Oakland, CA

140E. Antimicrobial Activity of Ceftaroline Combined with NXL104 Tested Against a Collection of Organisms Expressing Multiple β -Lactamases.

Helio S. Sader, M.D., Ph.D.,¹ *Gregory Williams, Ph.D.*,² Gary J. Moet, B.S.,¹ Mariana Castanheira, Ph.D.,¹ Ian Critchley, Ph.D.,² Ronald N. Jones, M.D.¹; (1)JMI Laboratories, North Liberty, IA; (2)Cerexa, Inc (a wholly owned subsidiary of Forest Laboratories, Inc, New York, NY), Oakland, CA

141E. Ertapenem Monotherapy versus Cefotetan/Metronidazole Combination Therapy in Colorectal Surgery Patients.

Noreen H. Chan-Tompkins, Pharm.D., Valerie Vuylsteke, Pharm.D., Sunil Bhat, M.D., David Medich, M.D.; Allegheny General Hospital, Pittsburgh, PA

142. Treatment of Urinary Tract Infections: Are Cephalosporins Associated with Failure?

Jeffrey A. Starkey, Pharm.D., Jeff R. Hurren, Pharm.D., Rachel M. Chambers, Pharm.D., Susan L. Davis, Pharm.D.; Henry Ford Hospital, Detroit, MI

143. Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam Administered by Prolonged Infusion in Morbidly Obese, Hospitalized Patients.

S. Christian Cheatham, Pharm.D.,¹ Megan R. Fleming, Pharm.D.,¹ Daniel P. Healy, Pharm.D.,² Christina E.K. Chung, Pharm.D.,³ Katherine M. Shea, Pharm.D.,⁴ Melissa L. Humphrey, Pharm.D. Candidate,⁵ *Michael B. Kaye, Pharm.D.*³; (1)St. Francis Hospitals and Health Centers, Beech Grove, IN; (2)James Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH; (3)Purdue University College of Pharmacy, Indianapolis, IN; (4)University Medical Center at Brackenridge, Austin, TX; (5)Purdue University College of Pharmacy, West Lafayette, IN

144. Influence of Serum and Albumin on Echinocandin Pharmacodynamics.

Aasya S. Nasar, Pharm.D., Nathan P. Wiederhold, Pharm.D.; University of Texas at Austin College of Pharmacy, San Antonio, TX

146E. CANVAS 1 and 2: Analysis of Clinical Response at Day 3 from 2 Phase III Trials of Ceftaroline Fosamil vs. Vancomycin Plus Aztreonam in the Treatment of Complicated Skin and Skin Structure Infections.

Tanya Baculik, M.D.,¹ Paul B. Eckburg, M.D.,¹ H. David Friedland, M.D.,¹ Lily Llorens, Ph.D.,¹ *Charles C. Schraa, Pharm.D.*,² Alena Jandourek, M.D.,¹ Gary Witherell, Ph.D.,¹ Dirk Thye, M.D.¹; (1)Cerexa, Inc (a wholly owned subsidiary of Forest Laboratories, Inc, New York, NY), Oakland, CA; (2)Forest Research Institute, Mechanicsville, VA

147E. FOCUS 1 and 2: Analysis of Clinical Response at Day 4 from 2 Phase III Trials of Ceftaroline Fosamil vs. Ceftriaxone in the Treatment of Community-Acquired Pneumonia.

Paul B. Eckburg, M.D.,¹ H. David Friedland, M.D.,¹ Lily Llorens, Ph.D.,¹ *Charles C. Schraa, Pharm.D.*,² Alena Jandourek, M.D.,¹ Gary Witherell, Ph.D.,¹ Dirk Thye, M.D.¹; (1)Cerexa, Inc (a wholly owned subsidiary of Forest Laboratories, Inc, New York, NY), Oakland, CA; (2)Forest Research Institute, Mechanicsville, VA

148E. Viridans Group Streptococci Treatment with Daptomycin: Multinational Experience.

Kenneth C. Lamp, Pharm.D.,¹ MinJung Yoon, MPH,¹ Ricardo L. Chaves, M.D., Ph.D.²; (1) Cubist Pharmaceuticals, Lexington, MA; (2)Novartis Pharma AG, Basel, Switzerland

149. Characteristics of Patients with De-escalated Antibiotics Based on Culture and Sensitivity Data: Impact on Hospital Re-admittance.

Kimberly Halton, Pharm.D., Jennifer Ng, Pharm.D., BCPS, Anthony Lucchi, Pharm.D., BCPS, Thara Damodaran, M.D.; Mercy Gilbert Medical Center, Gilbert, AZ

150. Assessment of Antibigram Use in Patients with Sepsis Transferred to a Tertiary Care Facility.

Meredith Jernigan, Pharm.D.,¹ Bonnie A. Falcione, Pharm.D., BCPS²; (1)University of Pittsburgh Medical Center, Pittsburgh, PA; (2)University of Pittsburgh School of Pharmacy, Pittsburgh, PA

151E. Experience with Daptomycin for Coagulase-Negative Staphylococcal Bacteremia with Elevated Vancomycin MICs.

Kenneth C. Lamp, Pharm.D., Elizabeth D. Hermsen, Pharm.D., MBA, BCPS (AQ-ID), Charu Gupta, M.S., MinJung Yoon, MPH; Cubist Pharmaceuticals, Lexington, MA

152. Daptomycin Use in Neutropenic Patients with Documented MRSA Bacteremia with High Vancomycin MICs.

John A. Segreti, M.D.,¹ *Dina Besece, Pharm.D.*,² Hurdle Anderson, Pharm.D.,² Charu Gupta, M.S.²; (1)Rush University Medical Center, Chicago, IL; (2)Cubist, Lexington, MA

153E. Improving Prescribing and Documentation of Immunization and Education in Patients Who Undergo Emergency Splenectomy.

Bonnie A. Falcione, Pharm.D., BCPS,¹ Elisabeth L. George, Ph.D.,² Richard D. Day, Ph.D.,³ Susan J. Skledar, BSPHarm, MPH¹; (1)University of Pittsburgh School of Pharmacy, Department of Pharmacy and Therapeutics; UPMC Presbyterian Hospital, Pittsburgh, PA; (2) University of Pittsburgh School of Nursing, UPMC Presbyterian Hospital, Pittsburgh, PA; (3)University of Pittsburgh Graduate School of Public Health, Department of Biostatistics, Pittsburgh, PA

154. Evaluation of Clinical Outcomes and Adverse Events When Administering Alternative Doses of Linezolid to Obese Patients.

Megan R. Fleming, Pharm.D.,¹ S. Christian Cheatham, Pharm.D.,¹ *Michael B. Kays, Pharm.D.*²; (1)St. Francis Hospitals and Health Centers, Beech Grove, IN; (2)Purdue University College of Pharmacy, Indianapolis, IN

155. Tigecycline Use and Selection of *Pseudomonas aeruginosa*.

Scott J. Bergman, Pharm.D., BCPS,¹ Bart A. Smith, Pharm.D.,² Vidya Sundareshan, M.D.,³ Janak Koirala, M.D.³; (1)Southern Illinois University–Edwardsville, Springfield, IL; (2) Southern Illinois University–Edwardsville, Benton, IL; (3)Southern Illinois University School of Medicine, Springfield, IL

156. Empiric Anti-MRSA Antibiotics for MRSA Pneumonia in a Community Hospital.

Paul Juang, Pharm.D., Jennifer S. Hardesty, Pharm.D.; St. Louis College of Pharmacy, St. Louis, MO

158. Pharmacokinetics and Pharmacodynamics of Meropenem in Morbidly Obese, Hospitalized Patients.

S. Christian Cheatham, Pharm.D.,¹ Megan R. Fleming, Pharm.D.,¹ Daniel P. Healy, Pharm.D.,² Christina E.K. Chung, Pharm.D.³ *Michael B. Kays, Pharm.D.*³; (1)St. Francis Hospitals and Health Centers, Beech Grove, IN; (2)James Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH; (3)Purdue University College of Pharmacy, Indianapolis, IN

159. Pharmacokinetic and Safety Analysis of High-Dose Moxifloxacin in a Morbidly Obese Individual.

S. Travis King, Pharm.D.,¹ Ngan H. Vo, Pharm.D., BCPS,¹ Andrew C. Faust, Pharm.D., BCPS,¹ Dipen Kadaria, M.D.,² John W. Thompson, M.D.,² Matthew W. Mabie, M.D.³; (1) Methodist University Hospital, Memphis, TN; (2)University of Tennessee Health Science Center, Memphis, TN; (3)Mid-South Pulmonary Specialists, Memphis, TN

161. Effect of Implementing an Electronic Order Menu for Trimethoprim-Sulfamethoxazole on Changing Prescriber Ordering Behavior and Decreasing Adverse Events in Elderly Outpatient Veterans.

Tina M. Khadem, Pharm.D., Kimberly MacKay, Pharm.D., Ronald Brown, R.Ph.; Portland VA Medical Center, Portland, OR

162. Evaluation of Colistimethate Use in the Shock Trauma Center at the University of Maryland Medical Center.

Jennifer L. Bailey, Pharm.D.; University of Maryland Medical Center, Baltimore, MD

163E. Isoniazid Blood Levels in Patients with Pulmonary Tuberculosis at a Tuberculosis Referral Center.

Fanak Fahimi, Pharm.D.,¹ Shadi Baniyasi, Pharm.D., Ph.D.,² Farzad Kobarfard, Pharm.D., Ph.D.,³ Payam Tabarsi, M.D.,⁴ Shabnam Hemmati, Pharm.D.,⁵ Jamshid Salamzadeh, Pharm.D., Ph.D.,⁶; (1)Pharmaceutical Care Department, Chronic Respiratory Disease Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti, Tehran, Iran; (2)Pharmaceutical Care Department, Virology Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University, Tehran, Iran; (3)Medicinal Chemistry Department, School of Pharmacy, Shahid Beheshti University M.C., Tehran, Iran; (4)Chronic Respiratory Disease Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University M.C., Tehran, Iran; (5)Clinical Pharmacy Department, School of Pharmacy, Shahid Beheshti University M.C., Tehran, Iran; (6)Clinical Pharmacy Department, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Managed Care**164E. The First Pharmacist-Based Warfarin Monitoring Service in Iran.**

Fanak Fahimi, Pharm.D.,¹ Shadi Baniyasi, Pharm.D., Ph.D., Babak Sharif-Kashani, M.D.,³ Zargham Hossein Ahmadi, M.D.,⁴ Jamshid Salamzadeh, Pharm.D., Ph.D.,⁵ Rocsanna Namdar, Pharm.D., Sara Mousavi, Pharm.D., Ph.D.,⁷ Shadi Ziaie, Pharm.D., Ph.D.,⁵ Leila Ghazi-Tabatabaei, Pharm.D.,⁸ Golnar Radmand, M.S.,⁹ Mohammad Reza Masjedi, M.D.¹⁰; (1) Pharmaceutical Care Department, Chronic Respiratory Disease Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti, Tehran, Iran; (2)Pharmaceutical Care Department, Virology Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University, Tehran, Iran; (3)Tobacco Prevention and Control Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran;

(4)Lung Transplantation Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; (5)Clinical Pharmacy Department, School of Pharmacy, Shahid Beheshti University M.C., Tehran, Iran; (6)University of Colorado Anschutz Medical Campus, Aurora, CO; (7)Clinical Pharmacy Department, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; (8)Pharmaceutical Care Department, Chronic Respiratory Disease Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Behesht, Tehran, Iran; (9)Epidemiology and Biostatistics Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; (10)Chronic Respiratory Disease Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Medication Safety

169. Medication Reconciliation: Comparing a Customized Medication History Form to a Standard Medication Form. (CAMPII 2).

Gina J. Ryan, Pharm.D.,¹ Jane M. Caudle, MLn,² Mary Rhee, M.D.,² Jamye M. Hickman, Ph.D.,³ Circe W. Tsui, M.S.,² Catherine S. Barnes, Ph.D.,² Jia Haomia, Ph.D.,⁴ David C. Ziemer, M.D., MPH²; (1)Mercer University College of Pharmacy and Health Sciences, Atlanta, GA; (2)Emory University School of Medicine, Atlanta, GA; (3)Southern Polytechnic State University, Marietta, GA; (4)Columbia School of Nursing, New York, NY

Nephrology

174. Impact of Pharmacist-Managed Erythropoiesis-Stimulating Agents Clinics for Non-dialysis Chronic Kidney Disease Patients.

Leah Flowers, Pharm.D.,¹ Sherrie Aspinall, Pharm.D., M.S.,² Fran Cunningham, Pharm.D.,³ Xinhua Zhao, Ph.D.,⁴ Kenneth Smith, M.D., M.S.,⁵ Roslyn Stone, Ph.D.,⁵ Chester Good, M.D., MPH,⁴ ESA Clinic Study Group⁶; (1)G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS; (2)VA Center for Medication Safety, Pittsburgh, PA; (3)VA Center for Medication Safety, Hines, IL; (4)VA Pittsburgh Health Care System, Pittsburgh, PA; (5)University of Pittsburgh, Pittsburgh, PA; (6)VA Pharmacists

176E. Evaluation of the MDRD and Cockcroft-Gault Equations for Sitagliptin Dosing.

Joanna Q. Hudson, Pharm.D.,¹ M. Shawn McFarland, Pharm.D.,² Brandon M. Markley, Pharm.D.,³ Paul Patel, M.D.⁴; (1)University of Tennessee Department of Clinical Pharmacy, Memphis, TN; (2)Alvin C. York Veterans Administration, Murfreesboro, TN; (3)University Medical Center of Southern Nevada, Las Vegas, NV; (4)Murfreesboro Medical Clinic, Murfreesboro, TN

177E. Effects of α -Lipoic Acid on Oxidative Stress in ESRD Patients Receiving IV Iron.

Arif Showkat, M.D., FASN,¹ *Joanna Q. Hudson, Pharm.D., FASN*,² William Bastnagel, M.D.¹; (1)University of TN College of Medicine, Memphis, TN; (2)University of Tennessee College of Pharmacy, Memphis, TN

Neurology

178E. Rasagiline and Antidepressant Use in Patients with Parkinson's Disease: Assessing the Occurrence of Serotonin Toxicity.

Jack J. Chen, Pharm.D.,¹ Michel Panisett, M.D.,² Sean Rhyee, M.D., MPH³; (1)Loma Linda University, Loma Linda, CA; (2)Notre-Dame Hospital-CHUM, Montreal, Quebec, Canada; (3)University of Massachusetts Medical School, Worcester, MA

179. Increased Frequency and Duration of Elevated Blood Pressure Measurements After IV Thrombolytics for Ischemic Stroke Is Not Associated with Increased Risk of Symptomatic Intracerebral Hemorrhage.

Meghan E. Groth, Pharm.D., Ashis H. Tayal, M.D., Melissa Tian, R.N., Jillian M. Szczesiul, Pharm.D.; Allegheny General Hospital, Pittsburgh, PA

Other

190. Qatar Pharmacists' Understanding, Attitudes, Practice and Perceived Barriers Related to Providing Pharmaceutical Care.

Maguy S. El Hajj, Pharm.D., Hassna S. Al Saeed, BSPharm, Maryam A. Khaja, BSPharm; Qatar University College of Pharmacy, Doha, Qatar

191. Endocrine and Metabolism PRN Updates and Report of the Benefit with an Online Journal Club.

Amy C. Donihi, Pharm.D.,¹ Rohit Moghe, Pharm.D.,² Emily Vescovi, Pharm.D.,³ Jennifer N. Clements, Pharm.D.,³ Rick Hess, Pharm.D.,⁴ Craig Logemann, Pharm.D.,⁵ Kent Porter, Pharm.D.⁶; (1)University of Pittsburgh Medical Center, Pittsburgh, PA; (2)Thomas Jefferson University Hospital, Philadelphia, PA; (3)Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA; (4)Bill Gatton College of Pharmacy, Johnson City, TN; (5)Iowa Health, Des Moines, IA; (6)Sanofi-Aventis, Lantana, TX

192. Factors That Influence Board Certification Among Pharmacy Practice Faculty in the United States.

Kristin Watson, Pharm.D., BCPS,¹ Kimberly A. Toussaint, Pharm.D.,² Joel C. Marrs, Pharm.D., BCPS,³ Deborah A. Sturpe, Pharm.D., BCPS,¹ Sarah L. Anderson, Pharm.D., BCPS,³ Stuart T. Haines, Pharm.D., BCPS¹; (1)University of Maryland School of Pharmacy, Baltimore, MD; (2)University of Maryland Medical Center, Baltimore, MD; (3)University of Colorado School of Pharmacy, Aurora, CO

193E. Bromfenac Ophthalmic Solution for Treating the Signs of Dry Eye Disease.

Simon P. Chandler, Ph.D.,¹ Sheri Rowen, M.D.,² Neal A. Sher, M.D.,³ James A. Gow, M.D.,¹ Timothy R. McNamara, Pharm.D.¹; (1)ISTA Pharmaceuticals, Inc, Irvine, CA; (2)Mercy Medical Center, Baltimore, MD; (3)Eye Care Associates, Minneapolis, MN

194E. Integrated Phase 3 Clinical Trials of Bromfenac Sodium Ophthalmic Solution Dosed Once Daily for Ocular Surgery.

Simon P. Chandler, Ph.D.,¹ Bonnie A. Henderson, M.D.,² Johnny L. Gayton, M.D.,³ James A. Gow, M.D.,⁴ Timothy R. McNamara, Pharm.D.⁴; (1)ISTA Pharmaceuticals, Irvine, CA; (2) Boston Eye Surgery & Laser Center, Boston, MA; (3)Eyesight Associates of Middle Georgia, Warner Robins, GA; (4)ISTA Pharmaceuticals, Inc, Irvine, CA

195E. The Ocular Comfort of Bepotastine Besilate Ophthalmic Solution 1.5% in a Safety Clinical Trial.

Jon I. Williams, Ph.D.,¹ Stacey Ackerman, M.D.,² Jung T. Dao, M.D.,³ Tushina A. Reddy, M.D.,⁴ Timothy R. McNamara, Pharm.D.,¹ James A. Gow, M.D.¹; (1)ISTA Pharmaceuticals, Inc, Irvine, CA; (2)Philadelphia Eye Associates, Philadelphia, PA; (3)Cornea Consultants of Arizona, Phoenix, AZ; (4)Shepherd Eye Center, Las Vegas, NV

196E. Bepotastine Besilate Ophthalmic Solution 1.5% Rapidly Demonstrated Near Clearance of Ocular Itch in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.

Julie C. Clark, M.D.,¹ Gordon L. Schooley, Ph.D.,² Jon I. Williams, Ph.D.,¹ *James A. Gow, M.D.,¹* Timothy R. McNamara, Pharm.D.¹; (1)ISTA Pharmaceuticals, Inc, Irvine, CA; (2) Advanced Analytics and Informatics, LLC, Rancho Santa Fe, CA

197E. Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5% Improves Reflective Ocular Itching Scores in a Placebo-Controlled Natural Exposure Study of Subjects with a Demonstrated History of Seasonal Allergic Rhinoconjunctivitis (SAR).

Jon I. Williams, Ph.D.,¹ Gary D. Berman, M.D.,² Ronald H. Saff, M.D.,³ Allan Stillerman, M.D.,⁴ *James A. Gow, M.D.,¹* Timothy R. McNamara, Pharm.D.¹; (1)ISTA Pharmaceuticals, Inc, Irvine, CA; (2)Allergy & Asthma Specialists, Minneapolis, MN; (3)Allergy & Asthma Diagnostic Treatment Center, PA, Tallahassee, FL; (4)Allergy & Asthma Specialists, PA, Minneapolis, MN

Pain Management/Analgesia

198. Bupivacaine Extended-Release Liposome Injection (DepoFoam® Bupivacaine) vs. Bupivacaine HCl: A Meta-analysis of Multimodal Trials of Doses Up to and Including 300 mg.

Joseph Dasta, M.S.,¹ Sonia Ramamoorthy, M.D.,² Gary Patou, M.D.,³ Raymond Sinatra, M.D., Ph.D.⁴; (1)The University of Texas College of Pharmacy, Austin, TX; (2)University of California at San Diego, San Diego, CA; (3)Pacira Pharmaceuticals, Parsippany, NJ; (4) Yale-New Haven Hospital, New Haven, CT

199. Off-Label, Low-Dose Ketamine as an Effective Adjunctive Therapy for Postoperative Analgesia.

Colleen M. Culley, Pharm.D., BCPS,¹ Susan J. Skledar, BSPHarm, MPH,¹ Tara Pummer, Pharm.D.,¹ Lois Pizzi, BSN, R.N.²; (1)University of Pittsburgh School of Pharmacy, Department of Pharmacy and Therapeutics, Pittsburgh, PA; (2)University of Pittsburgh Medical Center Shadyside Campus, Inpatient Pain Management Coordinator, Pittsburgh, PA

200. DepoFoam® Bupivacaine (DB; EXPAREL™; Bupivacaine Extended-Release Multivesicular Liposome Injection) Exhibits Pharmacokinetic Properties Consistent with Sustained-Release Characteristics.

Deedee Hu, Pharm.D.,¹ Erol Onel, M.D.,² Neil K. Singla, M.D.,³ Lakshmanasamy Somasundaram, M.D.,⁴ Jeff Gadsden, M.D.,⁴ William G. Kramer, Ph.D.,⁵ Admir Hadzic, M.D., Ph.D.¹; (1)Memorial Hermann Memorial City Medical Center, Houston, TX; (2)Pacira Pharmaceuticals, Inc, Ridgefield, CT; (3)Lotus Clinical Research, Inc, Pasadena, CA; (4)St. Luke's Roosevelt Hospital, New York, NY; (5)Kramer Consulting LLC, North Potomac, MD

201E. A Post Hoc Pooled Data Analysis to Evaluate the Gastrointestinal Tolerability Profile of Tapentadol Extended Release (ER) versus Oxycodone Controlled Release (CR) in Patients ≥ 75 Years of Age.

David Biondi, D.O.,¹ Jim Xiang, Ph.D.,¹ Mila Etropolski, M.D.,² Bruce Moskovitz, M.D.¹; (1)Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ; (2)Johnson & Johnson Pharmaceutical Research & Development, LLC, Titusville, NJ

202E. A Post Hoc Pooled Data Analysis to Evaluate Blood Pressure (BP) and Heart Rate (HR) Measurements in Patients with a Current or Prior History of Hypertension Who Received Tapentadol ER, Oxycodone CR, or Placebo in Chronic Pain Studies.

David Biondi, D.O.,¹ Jim Xiang, Ph.D.,¹ Mila Etropolski, M.D.,² Bruce Moskovitz, M.D.¹; (1)Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ; (2)Johnson & Johnson Pharmaceutical Research & Development, LLC, Titusville, NJ

203. Pharmacists' Perceptions and Knowledge Regarding Opioid Risk Evaluation and Mitigation Strategies (REMS) in Community and Ambulatory Practice.

Karen Marlowe, Pharm.D., BCPS, DAAPM, Emily McCoy, Pharm.D.; Auburn University/ University of Southern Alabama, Fairhope, AL

204. Meta-analysis of the Tolerability of Tapentadol.

Vanessa White, Pharm.D., Stephanie L. Ballard, Pharm.D.; Nova Southeastern University, Palm Beach Gardens, FL

Pharmacokinetics/Pharmacodynamics/Drug Metabolism/Drug Delivery**221E. Population Probability of Target Attainment of Telavancin at Different Levels of Renal Function Against Methicillin-Resistant *Staphylococcus aureus* in U.S. Medical Centers.**

Andras Farkas, Pharm.D., Catherine Hoffman, M.T., ASCP; Nyack Hospital, Nyack, NY

222. Drug-Drug Interaction of Eslicarbazepine Acetate with Antiepileptic Drugs.

Gary Maier, Ph.D.,¹ Mark Versavel, M.D., Ph.D., MBA,¹ Jacqueline Zummo, M.S., MPH, MBA,¹ David Blum, M.D.,¹ Jahnavi Kharidia, Ph.D.,¹ Patricio Soares-da-Silva, M.D., Ph.D.,² (1)Sunovion Pharmaceuticals, Inc, Marlborough, MA; (2)BIAL – Portela & Ca, SA, Mamede do Coronado, Portugal

224. Population Pharmacokinetics of Eslicarbazepine Acetate in Patients with Partial-Onset Seizures.

Jahnavi Kharidia, Ph.D.,¹ Mark Versavel, M.D., Ph.D.,¹ Qiang Lu, Ph.D.,² Jacqueline Zummo, M.S., MPH, MBA,¹ Elizabeth Ludwig, Pharm.D.,² Ted Grasela, Pharm.D., Ph.D.,² Jill Fiedler-Kelly, M.S.,² Gary Maier, Ph.D.,¹; (1)Sunovion Pharmaceuticals, Inc, Marlborough, MA; (2)Cognigen Corp, Buffalo, NY

225. Drug Monitoring System in Interstitial Fluid: Feasibility Studies of Valproic Acid, Methotrexate, Gentamicin, and Theophylline.

Tony K.L. Kiang, Ph.D.,¹ Urs O. Häfeli, Ph.D.,² Boris Stoeber, Ph.D.,³ Beverly Chua, DVM,⁴ Morris Pudek, Ph.D.,⁵ Mary H.H. Ensom, Pharm.D.,¹; (1)Faculty of Pharmaceutical Sciences, The University of British Columbia & Child and Family Research Institute, Vancouver, British Columbia, Canada; (2)Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada; (3)Departments of Mechanical and Electrical & Computer Engineering, The University of British Columbia, Vancouver, British Columbia, Canada; (4)Animal Care Centre, The University of British Columbia, Vancouver, British Columbia, Canada; (5)Vancouver General Hospital, Vancouver, British Columbia, Canada

226. Drug Monitoring System in Interstitial Fluid: A Preliminary Study of Vancomycin and Tacrolimus Drug Concentrations.

Tony K.L. Kiang, Ph.D.,¹ Urs O. Häfeli, Ph.D.,² Boris Stoeber, Ph.D.,³ Beverly Chua, DVM,⁴ Morris Pudek, Ph.D.,⁵ Mary H.H. Ensom, Pharm.D.,¹; (1)Faculty of Pharmaceutical Sciences, The University of British Columbia & Child and Family Research Institute, Vancouver, British Columbia, Canada; (2)Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada; (3)Departments of Mechanical and Electrical & Computer Engineering, The University of British Columbia, Vancouver, British Columbia, Canada; (4) Animal Care Centre, The University of British Columbia, Vancouver, British Columbia, Canada; (5)Vancouver General Hospital, Vancouver, British Columbia, Canada

227E. Bioequivalence of Immediate-Release Oxycodone with Aversion® Technology (IRO-A), IRO-A with Niacin, and a Commercially Available Oxycodone.

Mark T. Leibowitz, M.D.,¹ Cynthia A. Zamora, M.D., FCCP,¹ Albert W. Brzeczko, Ph.D.,² Jeffrey G. Stark, Ph.D.³; (1)Worldwide Clinical Trials Drug Development Solutions, Clinical Research Services, San Antonio, TX; (2)Acura Pharmaceuticals Inc, Technical Affairs, Palatine, IL; (3) Worldwide Clinical Trials Drug Development Solutions, Pharmacokinetics, Austin, TX

228. ADME Properties of [¹⁴C]-ACU-4429 Following a Single Oral Dose in Healthy Volunteers.

Suliman Al-Fayoumi, Ph.D., MBA,¹ John W. Chandler, M.D.,¹ Suresh Mallikaarjun, Ph.D.,² Shiva Patil, Ph.D.,² Ryo Kubota, M.D., Ph.D.¹; (1)Acucela Inc, Seattle, WA; (2)Otsuka Pharmaceutical Development & Commercialization, Inc, Rockville, MD

229. Lurasidone Pharmacokinetics: Assessment of the Potential for Drug-Drug Interactions.

Antony Loebel, M.D.,¹ Sheldon Preskorn, M.D.,² Yu-Yuan Chiu, Ph.D.,¹ Donald Sarubbi, Ph.D.,² Masaaki Ogasa, M.S.,² Josephine Cucchiaro, Ph.D.¹; (1)Sunovion Pharmaceuticals, Inc, Ft. Lee, NJ; (2)Clinical Research Institute, Wichita, KS

230. Compatibility of Adenosine with Iodinated Contrast Agents.

Sulayma Naser Agha, B.S., Nicholas B. Norgard, Pharm.D., Edward M. Bednarczyk, Pharm.D.; University at Buffalo – School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY

231. Relative Bioavailability of Oral Fosphenytoin Sodium Injection in Healthy Volunteers.

Kevin Kaucher, Pharm.D.,¹ Curtis E. Haas, Pharm.D.,² Nicole M. Acquisto, Pharm.D.,² Jeff Huntress, Pharm.D.,³ David C. Kaufman, M.D.⁴; (1)Denver Health Medical Center, Denver, CO; (2)University of Rochester Medical Center, Rochester, NY; (3)University of Rochester Medical Center – Highland Hospital, Rochester, NY; (4)University of Rochester, School of Medicine and Dentistry, Rochester, NY

232. Vascular Protection with Candesartan: Beyond Blood Pressure Reduction.

Ahmed Alhusban, Pharm.D., Anna Kozak, M.S., Susan C. Fagan, Pharm.D.; Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, Charlie Norwood VA Medical Center, Augusta, GA

233. Nephrotoxicity Associated with Weight-Based Vancomycin Dosing.

Megan Brockman, Pharm.D.,¹ A. Shaun Rowe, Pharm.D., BCPS²; (1)The University of Tennessee Medical Center, Knoxville, TN; (2)The University of Tennessee College of Pharmacy, Knoxville Campus, Knoxville, TN

234. Candesartan for Prostate Cancer: A Dose or a Class Effect?

Ahmed Alhusban, Pharm.D., Ahmad Al-azayzih, Pharm.D., Diana Houg, Pharm.D., Susan C. Fagan, Pharm.D., Somanath P.R. Shenoy, Ph.D.; Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy; Charlie Norwood VA Medical Center, Augusta, GA

236E. Pharmacokinetic Interactions of Roflumilast with Medications Commonly Prescribed for COPD Patients.

Phillip Jennings, Pharm.D.,¹ Gezim Lahu, M.S.,² Abhijeet Jakate, Ph.D.,¹ Andreas Hunnemeyer, M.D., M.S.,² Nassr Nassr, M.D.²; (1)Forest Research Institute, Jersey City, NJ; (2)Nycomed GmbH, Konstanz, Germany

237. The Effects of Repeat Doses of Albiglutide on the Pharmacokinetics and Pharmacodynamics of a Low-Dose Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol.

Mark Bush, Ph.D.,¹ Rhona Scott, Ph.D.,² Hui Zhi, Ph.D.,³ Prapoch (Keng) Watanalumlerd, Ph.D.,⁴ Eric Lewis, M.D.¹; (1)GlaxoSmithKline, Research Triangle Park, NC; (2) GlaxoSmithKline, Middlesex UB11 IBT, United Kingdom; (3)GlaxoSmithKline, Research Triangle Park, NC; (4)PPD, Richmond, VA

238. Inadequate Empirical Vancomycin Dose in Non-elderly Neurosurgical Patients by Conventional Dosing Regimen.

Ming-Fang Wen, M.S.,¹ Ting-Ya Yang, M.S.,² Fe-Lin Lin Wu, Ph.D.,² Li-Jiuan Shen, Ph.D.²; (1)Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan; (2) Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan

239E. Pharmacokinetics, Cord Blood Concentrations, and Tolerability of Boosted Fosamprenavir in Pregnancy.

Michelle S. Cespedes, M.D.,¹ Susan L. Ford, Pharm.D.,² Gary E. Pakes, Pharm.D.,² Luis Vargas, B.S.,¹ Eleanor M. De Candia, R.N.,¹ Judith A. Aberg, M.D.¹; (1)New York University School of Medicine, New York, NY; (2)GlaxoSmithKline, Research Triangle Park, NC

240. Evaluation of Newer Equations for Estimation of Renal Function for Utility in Drug Dosing Using an Aminoglycoside Pharmacokinetic Model.

Jeremy Fox, Pharm.D., BCPS, Charles H. Rawls III, Pharm.D.; Shenandoah University, Winchester, VA

241E. Clinical Pharmacokinetics of Low-Dose Cidofovir without and with Concomitant Probenecid Used for the Treatment of Persistent BK Viremia in Renal Transplant Recipients.

Jeremiah D. Momper, Pharm.D., Yang Zhao, Ph.D., Ron Shapiro, M.D., Parmjeet Randhawa, M.D., Kristine Schonder, Pharm.D., Raman Venkataramanan, Ph.D.; University of Pittsburgh, Pittsburgh, PA

242. Progesterone, a Female Sex Hormone, Inhibits CYP3A-Mediated Metabolism of 17-Alpha Hydroxyprogesterone Caproate, an Agent that Prevents Preterm Birth.

Yang Zhao, Ph.D.,¹ Courtney Cuppett, M.D.,² WenChen Zhao, M.S.,¹ Shimin Zhang, M.S.,¹ Steve Caritis, M.D.,² Raman Venkataramanan, Ph.D.¹; (1)University of Pittsburgh, Pittsburgh, PA; (2)Magee-Women's Hospital, Pittsburgh, PA

243. PK/PD Modeling and Simulations Support Development of MN-221, a Novel, Highly Selective Beta2-Adrenergic Agonist for Treatment of Acute Asthma.

Kirk Johnson, Ph.D.,¹ James R. Bosley, Ph.D.,² Ron Beaver, Ph.D.²; (1)MediciNova, Inc, San Diego, CA; (2)Rosa & Co. LLC, San Carlos, CA

Pulmonary**249. Appropriateness of Chronic Obstructive Pulmonary Disease (COPD) Management per Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines at a Family Medicine Practice.**

C. Brock Woodis, Pharm.D.,¹ Amber N. McLendon, Pharm.D.,² Cheryl Van Horn, R.N.,³ Dallas Brooks, Pharm.D. Candidate,² Caroline Ferguson, Pharm.D. Candidate,² Justin

Spivey, Pharm.D. Candidate²; (1)Campbell University College of Pharmacy and Health Sciences and Duke University Department of Community and Family Medicine, Durham, NC; (2)Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC; (3)Duke University Department of Community and Family Medicine, Durham, NC

250. Cost-Effectiveness Analysis of Roflumilast/Tiotropium Combination Therapy vs. Tiotropium Monotherapy in Patients with Severe to Very Severe COPD.

Andrew P. Yu, Ph.D.,¹ *Shawn Sun, Ph.D.*,² Maryna Marynchenko, MBA,¹ Ritesh Banerjee, Ph.D.,¹ Michelle MocarSKI, MPH,² Donald Yin, Ph.D.,² Eric Wu, Ph.D.¹; (1)Analysis Group, Boston, MA; (2)Forest Research Institute, Jersey City, NJ

251. The Safety and Efficacy of Roflumilast: A New Treatment to Reduce Exacerbation Risk in Severe COPD Patients.

Nicola A. Hanania, M.D., M.S., FCCP, FRCP(C), FACP,¹ Mark T. Dransfield, M.D.,² Udo-Michael Goehring, M.D.,³ Hans Mosberg, M.D.,³ *Phillip Jennings, Pharm.D.*⁴; (1) Baylor College of Medicine, Houston, TX; (2)University of Alabama, Birmingham, AL; (3)Department of Medical Scientific Strategy/Respiratory, Nycomed, GmbH, Konstanz, Germany; (4)Forest Research Institute, Jersey City, NJ

252E. An Evaluation of the Management of Non-Life-Threatening COPD Exacerbations in Hospitalized Patients.

J. Andrew Woods, Pharm.D., BCPS,¹ Christopher K. Finch, Pharm.D., BCPS,² Justin B. Uesry, Pharm.D., BCPS,² Timothy H. Self, Pharm.D.²; (1)Wingate University, School of Pharmacy, Wingate, NC; (2)Methodist University Hospital and University of Tennessee, Memphis, TN

253E. An Evaluation of Inhaled Bronchodilator Therapy in Patients Hospitalized for Non-Life-Threatening COPD Exacerbations.

J. Andrew Woods, Pharm.D., BCPS,¹ Timothy H. Self, Pharm.D.,² Shaunta' M. Ray, Pharm.D., BCPS,³ Justin B. Uesry, Pharm.D., BCPS,² Christopher K. Finch, Pharm.D., BCPS²; (1)Wingate University, School of Pharmacy, Wingate, NC; (2)Methodist University Hospital and University of Tennessee, Memphis, TN; (3)The University of Tennessee College of Pharmacy, Knoxville, TN

Rheumatology

254E. Febuxostat (FEB) vs. Allopurinol (ALLO) in Treating the Hyperuricemia of Gout in Diabetic Patients.

Michael A. Becker, M.D.,¹ Patricia MacDonald, N.P.,² Barbara Hunt, M.S.,² Robert L. Jackson, M.D.²; (1)University of Chicago, Pritzker School of Medicine, Chicago, IL; (2) Takeda Global Research & Development Center, Inc, Deerfield, IL

255E. Pharmacokinetics and Pharmacodynamics of Tocilizumab in Systemic Juvenile Idiopathic Arthritis.

Xiaoping Zhang, Ph.D.,¹ Peter N. Morcos, Pharm.D.,¹ Fabrizio De Benedetti, M.D., Ph.D.,² Hermine Brunner, M.D., M.S.,³ Nicolino Ruperto, M.D., MPH,⁴ Felicity Schaefer, M.S.,¹ Stephanie Roseti, R.N., MSN, APN-BC,¹ Andy Kenwright, B.S.,⁵ Alberto Martini, M.D.,⁴ Daniel Lovell, M.D., MPH³; (1)Roche, Nutley, NJ; (2)IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy; (3)Pediatric Rheumatology Collaborative Study Group, Cincinnati, OH; (4)PRINTO-IRCCS Giannina Gaslini, Genova, Italy; (5)Roche, Welwyn, United Kingdom

256E. Long-term Safety of Tocilizumab in Rheumatoid Arthritis Clinical Trials.

Mark C. Genovese, M.D.,¹ Anthony Sebba, M.D.,² Andrea Rubbert-Roth, M.D.,³ Juan J. Scali, M.D.,⁴ Moshe Zilberstein, M.D.,⁵ Liz Thompson, B.S.,⁶ Ronald F. van Vollenhoven, M.D.⁷; (1)Stanford University Medical Center, Stanford, CA; (2)University of South Florida, Palm Harbor, FL; (3)University of Cologne, Cologne, Germany; (4)Durand Hospital, Buenos Aires, Argentina; (5)Roche, Nutley, NJ; (6)Roche, Welwyn, United Kingdom; (7) Karolinska Institute, Stockholm, Sweden

CLINICAL PHARMACY FORUM

These abstracts describe the delivery, development, justification, or documentation of an innovative clinical pharmacy service; they may be descriptive only and need not contain an evaluative component.

Community Pharmacy Practice

299. Community Pharmacist Clinical Documentation Intervention Project.

Jamie L. McConaha, Pharm.D., Robert L. Maher, Pharm.D.; Duquesne University Mylan School of Pharmacy, Pittsburgh, PA

300. Implementation of a Herpes Zoster Immunization Service at an Independent Community Pharmacy.

Karen M. Horbowicz, Pharm.D.; Inman Pharmacy, Inc, Cambridge, MA

301E. Identifying Medication-Related Needs of HIV Patients: Foundation for Community Pharmacist-Based Services.

Yardlee S. Kauffman, Pharm.D.,¹ Melissa McGivney, Pharm.D., FCCP,¹ Elana Barkowitz, MPH,² Nicole Cerussi, Pharm.D., MPH,³ Jan L. Pringle, Ph.D.¹; (1)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (2)University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA; (3)UPMC Falk Pharmacy, Pittsburgh, PA

302. The Role of a Community Pharmacy Resident in Expanding Clinical Pharmacy Services Within a Traditional Dispensing Model.

Jamie Montgomery, R.Ph., BCPP, Ted J. Turner, Pharm.D., Melanie Quinn, Pharm.D., Jessica Harms, Pharm.D., Sheila Samol, Pharm.D., Tanya Fabian, Pharm.D., Ph.D., BCPP; Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA

303E. Assessing Community Pharmacist Impact on Over-the-Counter Medication Selection.

Jamie L. McConaha, Pharm.D.,¹ Jennifer E. Heasley, Pharm.D.,¹ Thomas J. Mattei, Pharm.D.²; (1)Duquesne University Mylan School of Pharmacy, Pittsburgh, PA; (2)Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA

Drug Information

308. Carbapenems Selection by Means of the SOJA Method.

Ana Leandro, Pharm.D., Armando Alcobia, Pharm.D.; Hospital Garcia de Orta, Almada, Portugal

309. Standard Operating Procedure to Develop Evidence-Based Information to Support Pharmacy and Therapeutics Committee Decision for Formulary Management at a University Hospital.

Ana C. Ribeiro Rama, Ph.D.; Pharmacy Department, Coimbra University Hospitals and Center for Pharmaceutical Studies, Faculty Pharmacy, Coimbra University, Coimbra, Portugal

Emergency Medicine

317. A Retrospective Review of Medication Orders Entered for Emergency Department Patients Within an Academic Teaching Medical Center for Quality Assurance.

Jason W. Lancaster, Pharm.D., BCPS; Northeastern University, Department of Pharmacy Practice/Lahey Clinic Medical Center, Boston, MA

318. Implementation and Evaluation of a Recombinant Activated Factor VII Guideline for Uncontrolled Bleeding.

Nicole M. Acquisto, Pharm.D., Paul E. Bankey, M.D., Ph.D., Curtis E. Haas, Pharm.D.; University of Rochester Medical Center, Rochester, NY

319. Benchmarking Enoxaparin Use in the Emergency Department as a Quality Improvement Metric for Clinical Pharmacy Services.

Matthew S. Nelson, Pharm.D., Natasha D. Lopez, Pharm.D., Candice R. Preslaski, Pharm.D., Elena Santayana, Pharm.D., BCPS, Ishaq Lat, Pharm.D., BCPS; University of Chicago Medical Center, Chicago, IL

320. Evaluation of a Pharmacist Oversight Program for Medication Use in the Emergency Department of an Academic Medical Center.

Sally Rafie, Pharm.D., Theodore Chan, M.D., Edward Castillo, Ph.D., Douglas Humber, Pharm.D., Ronald Dunlay, Pharm.D.; UC San Diego Health System, San Diego, CA

Family Medicine

322E. Incorporating Pharmacy Services Within a Family Medicine Residency Home Visit Program.

Tanya M. Dougherty, Pharm.D., BCPS,¹ Heather A. Klusaritz, MSW,² Peter F. Cronholm, M.D., MSCE,² Nishaminy Kasbekar, Pharm.D., B.S., FASHP³; (1)Penn Presbyterian Medical Center, Department of Family Medicine and Community Health, University of Pennsylvania, Philadelphia, PA; (2)Department of Family Medicine and Community Health, University of Pennsylvania, Philadelphia, PA; (3)Penn Presbyterian Medical Center, Philadelphia, PA

323. COPD Free Medication Initiative.

Jennie Broders, Pharm.D., BCPS, Patricia Klatt, Pharm.D., BCPS, Isabel MacKinney-Smith, BSN, R.N.; UPMC St. Margaret, Pittsburgh, PA

Infectious Diseases

330. Development, Implementation, and Assessment of a Pilot Pharmacy Vancomycin Dosing Service (PVDS).

Andrea Pallotta, Pharm.D., Elizabeth A. Neuner, Pharm.D., BCPS, Jennifer K. Sekeres, Pharm.D., BCPS, Jeffrey Ketz, Pharm.D., BCPS, Jason Skok, ITD, Nabin Shrestha, M.D., MPH, FACP, FIDSA; Cleveland Clinic, Cleveland, OH

331. Incidence of Supratherapeutic Trough Concentrations in Elderly Patients with Aggressive Vancomycin Dosing.

Nicole L. Metzger, Pharm.D., Faizan A. Mirza, Pharm.D., Kathryn M. Momary, Pharm.D.; Mercer University College of Pharmacy and Health Sciences, Atlanta, GA

332. Use of the Clinical Pulmonary Infection Score (CPIS) to Guide Duration of Antibiotic Therapy in Medical Intensive Care Unit (MICU) Patients with Health Care-Associated Pneumonia (HCAP).

Jill Jessmer, Pharm.D., Maribeth Pauli, Pharm.D., Marina Yazdi, Pharm.D., Mojdeh Saba, Pharm.D., Claire Chan, Pharm.D., Jonathan Siner, M.D., Jeffrey Topal, M.D.; Yale-New Haven Hospital, New Haven, CT

334. Surveillance of Antibiotic Resistance at a Tertiary Institution in Trinidad.

Patricia I. Sealy, Pharm.D., Ph.D.,¹ Madhura Manjunath, M.D.²; (1)The University of the West Indies, Faculty of Medical Sciences, School of Pharmacy, Port-of-Spain, Trinidad and Tobago; (2)Ministry of Health, Port-of-Spain, Trinidad and Tobago

Managed Care

335E. Improving Documentation of the Value of Clinical Pharmacy Interventions in an Integrated Health Care Delivery System.

Sheryl J. Herner, Pharm.D., BCPS,¹ Robin R. Hill, Pharm.D., BCPS,¹ Samuel G. Johnson, Pharm.D., BCPS,² C. Ryan Lowe, Pharm.D., BCPS,² Lea C. Price, Pharm.D., BCPS³; (1) Kaiser Permanente, Aurora, CO; (2)Kaiser Permanente, Denver, CO; (3)Kaiser Permanente, Lafayette, CO

Other

341. Pharmaceutical Appointment in Clinical Trials.

Sebastião Ferreira da Silva, Pharm.D., Isabel Gomes, Pharm.D., Ana Luísa Vital, Pharm.D., Marta Nabais, Pharm.D., José Feio, Pharm.D.; Hospitais da Universidade de Coimbra, Coimbra, Portugal

342. Analysis of Pharmacist-Driven Medication Reconciliation Services on Hospital Readmission Rates, Emergency Room Visits, and Hospital Length of Stay.

Paula A. Helton, Pharm.D., BCPS, CGP, Susan C. Woodard, Pharm.D., BCPS, CGP; VA Tennessee Valley Health Care System, Nashville, TN

Pain Management/Analgesia

343. Pharmacist-Led and Interdisciplinary Model for Management of Adult Cancer Pain in a Medical Center.

Yuan-Hsun Ko, B.S.,¹ Yu-Hsuan Yen, M.S.,² Mantzu M. Wu, Pharm.D.,³ Kuei-Ju Cheng, Pharm.D.,¹ Hsiang-Yin Chen, Pharm.D., M.S.⁴; (1)Department of Pharmacy, Taipei Medical University–Wanfang Hospital, Taipei, Taiwan; (2)Taipei Medical University–Wanfang Hospital, Taipei, Taiwan; (3)Taipei Medical University–Wanfang Hospital, Taipei, Taiwan; (4)Taipei Medical University–Wanfang Hospital, Taipei, Taiwan

344. An Interdisciplinary Approach to Reducing Opioid Analgesic Misuse in Patients with Chronic Noncancer Pain in the Primary Care Setting.

Michele L. Matthews, Pharm.D., CPE,¹ Robert N. Jamison, Ph.D.,² Edgar Ross, M.D.,² Elizabeth M. Scanlan, N.P.,² Lori W. Tishler, M.D.³; (1)Massachusetts College of Pharmacy and Health Sciences, Boston, MA; (2)Brigham and Women’s Hospital Pain Management Center, Chestnut Hill, MA; (3)Brigham and Women’s Hospital, Phyllis Jen Center for Primary Care, Boston, MA

LATE BREAKERS

These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoeconomics, and pharmacoepidemiology.

ADR/Drug Interactions

473. Clindamycin-Induced Acute Kidney Injury: Is This for Real?

Nidhi Bansal, MBBS, Jiwana Thapa, MBBS; SUNY Upstate Medical University, Syracuse, NY

474. Adverse Drug Reactions in Ambulatory Care with an Electronic Medical Record and Electronic Prescribing: Identification and Characterization.

Katy E. Trinkley, Pharm.D., Harrison G. Weed, M.D., M.S., FACP, Stuart J. Beatty, Pharm.D., BCPS, Milap C. Nahata, Pharm.D., M.S., FCCP; Ohio State University Colleges of Pharmacy and Medicine, Columbus, OH

Ambulatory Care

475. Effectiveness of a Pharmacist-Managed Hypertension Shared Medical Appointment.

Rachel N. Chandra, Pharm.D.; Dayton Veterans Affairs Medical Center, Dayton, OH

Cardiovascular

476E. Is Anemia Associated with Heart Failure? NHANES Database (2005-2006) Analysis.

Abdulkhalig J. Alsaman, M.S., Yousef N. Alhashem, M.S., Ali M. Alhammad, M.S., Maitham A. Al Hawaj, B.S., Mohammed A. Al Mohaini, B.S., Spencer E. Harpe, Pharm.D., Ph.D., MPH, Benjamin W. Van Tassell, Pharm.D., BCPS; Virginia Commonwealth University, Richmond, VA

477. Blockade of Sodium Entry Ameliorates Arrhythmias During Calcium Overload.

Przemyslaw Radwanski, Pharm.D., Ph.D., Steven Poelzing, Ph.D.; University of Utah, Salt Lake City, UT

Community Pharmacy Practice

478. A Community Pharmacy, Diabetes Management Program to Improve Biometric and Cardiac Risk Factors.

Jamie Vortherms, Pharm.D., Michael Taitel, Ph.D., Leonard Fensterheim, MPH, Heather Kirkham, Ph.D., Ian Duncan, FSA; Walgreens, Deerfield, IL

Education/Training

479E. The Effect of Integration of Pharmaceutical Care Components in Pharmacy Schools Curricula on Medication Adherence in Syria.

Anas Bahnassi, Ph.D.; Arab International University, Damascus, Syria

480. Evaluation of Pharmacy Resident Perceptions, Knowledge, and Interventions Following a Trauma Response Training Program.

Stephen Rolfe, Pharm.D., BCP,¹ Kimberly A. Pesaturo, Pharm.D., BCPS,² Jeffrey Dandurand, Pharm.D., BCPS³; (1)University of New England, College of Pharmacy, Portland, ME; (2)Massachusetts College of Pharmacy and Health Sciences – Worcester/Manchester, Worcester, MA; (3)Clinical Pharmacy Associates, Laurel, MD

481. Pursuit of Post-graduate Training Programs upon Graduation.

Olga Hilas, Pharm.D., BCPS, CGP, Sharon See, Pharm.D., BCPS; St. John's University College of Pharmacy and Allied Health Professions, Queens, NY

482. Assessment of the Prevalence, Structure and Function of "Informal" Student Chapters of ACCP.

Andrew Smith, Pharm.D.; UMKC School of Pharmacy, Kansas City, MO

Emergency Medicine

483. Development of a Pharmacy Computerized Inventory Program (PCIP) in an Emergency Department/Intensive Care Unit, Outpatient Care, and a Pediatric Hospital in Haiti.

Michelle Holm, Pharm.D., R.Ph.,¹ John Rueter, R.Ph.,¹ Maria Rudis, Pharm.D., R.Ph.,¹ Chris Arendt, Pharm.D., R.Ph.,¹ Nikki Jensen, IT Coordinator²; (1)Mayo Clinic, Rochester, MN; (2) PlanetJ Corp, Escondido, CA

Geriatrics

484. Clinical Interventions of Pharmacy Practice Residents on an Acute Care for Elders Unit.

Olga Hilas, Pharm.D., MPH, BCPS, CGP; St. John's University College of Pharmacy and Allied Health Professions, Queens, NY

Medication Safety

485. Evaluation of Infusion-Related Reactions with Iron Sucrose at a Large Tertiary Medical Center.

Diana R. Mack, Pharm.D.,¹ Leigh Anne Hylton Gravatt, Pharm.D., BCPS,² Spencer E. Harpe, Pharm.D., Ph.D., MPH²; (1)Virginia Commonwealth University Health System, Richmond, VA; (2)Virginia Commonwealth University School of Pharmacy, Richmond, VA

Psychiatry

486E. Effects of Pharmacist Drug Regimen Reviews on Physicians' Compliance with Recommended Laboratory Monitoring Criteria for Psychotropic Medications at a State Supported Living Center.

Abimbola Farinde, Pharm.D., M.S., FASCP, FACA, BCPP, CGP; Lufkin State Supported Living Center, Pollok, TX

Transplant/Immunology

487E. Impact of Conversion to Sirolimus-Based Immunosuppression on Fibrosis Progression in HCV+ Liver Transplant Recipients.

Christin Rogers, Pharm.D.,¹ Daniel R. Stevens, B.S.,² Michael Curry, M.D.¹; (1)Beth Israel Deaconess Medical Center, Boston, MA; (2)Northeastern University, Boston, MA

PRN History Paper

488. Drug Information Practice and Research Network History: 2002–2009

Kristina E. Ward, Pharm.D., B.S., BCPS,¹ Beatriz Manzor Mitrzyk, Pharm.D., BCPS,² Philip J. Gregory, Pharm.D.,³ Andrea L. McKeever, Pharm.D., BCPS⁴; (1)University of Rhode Island, Kingston, RI; (2)Mitrzyk Medical Communications, LLC, Northville, MI; (3)Center for Drug Information and Evidence-Based Practice (CDIEBP), Creighton University School of Pharmacy and Health Professions, Omaha, NE; (4)South University School of Pharmacy, Savannah, GA

Infectious Diseases

489. Opportunities to Improve Fluoroquinolone Prescribing: A Pilot Study.

Robert Eastin, Pharm.D., Amie Nguyen, Pharm.D., Maggie Brownell, Pharm.D., Donna Agan, Ed.D., Harminder Sikand, Pharm.D. Scripps Mercy Hospital San Diego, CA; Scripps Memorial Hospital La Jolla, CA

